SPOTLIGHT: Committee backs Via trials


Shares of Via Pharmaceuticals jumped this morning after a monitoring committee endorsed safety and efficacy data for two mid-stage trials of VIA-2291, its lead therapy for cardiovascular disease. Top-line results are expected next year. Release

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.